Onkos Surgical Announces Definitive Agreement to Acquire the JTS Extendible Prosthesis

Onkos Surgical, Inc., a rapidly growing, leading innovator of solutions for musculoskeletal oncology and complex orthopaedic conditions, announced today that it has entered into a definitive agreement with Stryker to acquire the Juvenile Tumour System (JTS).

The system enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.

Onkos is a specialty MedTech company that is focused on developing solutions for surgeons who specialize in musculoskeletal oncology and other complex orthopaedic conditions.

The JTS is a device that allows for non-invasive lengthening of the implant post-surgery over time in a clinical setting. The design eliminates the need for multiple lengthening surgeries, anesthesia, or sedation, and therefore helps reduce the risk of complications and cost associated with limb reconstruction surgery.

“This is a significant day for Onkos Surgical and the musculoskeletal oncology community,” said Patrick Treacy, Co-Founder and CEO. “Our ‘Why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission. We are committed to being good stewards of the technology. We are proud to collaborate with this dedicated surgeon community and excited to create a bright future for the technology as we continue this meaningful work for pediatric musculoskeletal cancer patients.”

Onkos Surgical is a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic conditions. With our Precision Orthopaedics solutions, surgeons are better informed about patient-specific clinical challenges and are able to plan and implement a more precise reconstruction. Our personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D anatomic modeling and printing, implant design, and workflow optimization. More than 350 of the leading academic medical institutions in the US choose Onkos Surgical Precision Orthopaedics.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version